Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01997190 · ClinicalTrials.gov registry record · Phase 1
Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
A Phase 1 study, sponsored by Candel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT01997190 is a Phase 1 study that has completed, run by Candel Therapeutics. The registered enrollment target is 19 participants.
The verdict
NCT01997190, a Phase 1 study, has completed, sponsored by Candel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a phase I study of intrapleural AdV-tk therapy in patients with malignant pleural effusion (MPE). The primary objective is to test the safety of intrapleural AdV-tk therapy. Secondary objectives are to evaluate clinical efficacy and biologic activity
Interventions
- BIOLOGICAL AdV-tk + valacyclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2013-10 |
| Est. Completion | 2018-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01997190
The ClinicalTrials.gov registry entry for NCT01997190 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Candel Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AdV-tk + valacyclovir is the first listed.
NCT01997190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01997190 about?
NCT01997190 is a clinical study titled "Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion". This is a phase I study of intrapleural AdV-tk therapy in patients with malignant pleural effusion (MPE). The primary objective is to test the safety of intrapleural AdV-tk therapy. Secondary objectives are to evaluate clinical efficacy and biologic activity
What is the current status of trial NCT01997190?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2013-10. Estimated completion is 2018-02.
What interventions are being tested in trial NCT01997190?
The interventions under investigation include: AdV-tk + valacyclovir (BIOLOGICAL).
Who is sponsoring clinical trial NCT01997190?
This trial is sponsored by Candel Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.